Impact of new lipid management guidelines on the treatment of extreme and very high‐risk patients: AACE/ACE and AHA/ACC guidelines
Year: 2019
Type: article
Abstract: In February 2017, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) published an update of theirGuidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease.While several topics were updated in the AACE/ACE Guideline, including strategies to assess cardiovascular disease (CVD) risk and treat dyslipidemia in type 1 diabetes, the most substantial changes pertained to atherosclerotic cardiovascular disease (ASCVD) risk categories and low-density lipoprotein cholesterol (LDL-C) goal categorization.For the first time, an "Extreme Risk" category was established, along with the most aggressive LDL-C-lowering goals recognized by any scientific organization to that date. 1 The evidence for and treatment implications related to this change, both in general and in context with the recently published American College of Cardiology/ American Heart Association (ACC/AHA) Guideline on the Management of Blood Cholesterol, 2 are discussed below.
Source: Journal of Diabetes
Author: Paul S. Jellinger
Institution: University of Miami
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2990798741